TP53 and colon carcinoma: To understand their contributions in cellular responses to DNA-damaging anticancer drugs, we treated isogenic human colon carcinoma HCT 116 cells with varying doses of doxorubicin, analyzing wild-type (WT), p53−/−, and p21−/− cell lines.